Cristin-person-ID: 14799
Person

Tormod Kyrre Guren

  • Stilling:
    Overlege
    ved Onkologisk fagseksjon 2 ved Oslo universitetssykehus HF
  • Stilling:
    Overlege
    ved Onkologisk fagseksjon 2 ved Oslo universitetssykehus HF

Resultater Resultater

Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy.

Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Christoffersen, Thoralf; Lingjærde, Ole Christian; Tveit, Magne Kjell; Kure, Elin Wenche Hegland mfl.. 2018, Annals of Oncology. Uu, RS, OUH, HAUKELAND, UIO, OUS, UIBSammendrag/abstract

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer.

Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yoshino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotios; Hong, Yong Sang mfl.. 2019, The New England quarterly. USA, VHEBRON, OUH, KUL, MSKCC, RUSSLAND, STORBRITAN, SUDSDN, OUS, UTM, HGMA, PETERMAC, NKIAVL, JAPAN, BELGIA, UoU, ICOSTAMUOL, ITALIA, UCLVitenskapelig artikkel

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

Kopetz, Scott; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Gollerkeri, A; Maharry, K mfl.. 2019, Annals of Oncology. OUS, UTMSammendrag/abstract

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

Nathan, Paul; Ascierto, Paolo A.; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen mfl.. 2019, European Journal of Cancer. RUSHEALTH, UoM, UAdM, NKIAVL, NHS, TYSKLAND, CIBER, COI, VHEBRON, HELLAS, UK-ESSEN, UOA, UdSdT, OUS, MUW, ET, SSN, MVCN, HGMA, TUMORI, UNISI, UNILUEBECK, NHSSCOT, NCL, BRI, LAPAZ, USZ, KREVitenskapelig artikkel

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

Schadendorf, Dirk; Ascierto, Paolo Antonio; Haanen, John; Espinosa, Enrique; Demidov, Lev; Garbe, Claus; Guida, Michele; Lorigan, Paul; Chiarion-Sileni, Vanna; Gogas, Helen mfl.. 2019, European Journal of Cancer. MHH, RUSHEALTH, UoM, UAdM, NKIAVL, NHS, CIBER, TYSKLAND, COI, VHEBRON, UK-ESSEN, HELLAS, UOA, UdSdT, OUS, MUW, SSN, ET, MVCN, HGMA, TUMORI, UNILUEBECK, UNISI, NHSSCOT, NCL, BRI, USZ, KREVitenskapelig artikkel
1 - 5 av 42 | Neste | Siste »